PhenoPath, PLLC is a physician-owned specialty pathology practice and reference laboratory providing diagnostic and contract research services to pathology and oncology practices, hospitals, biopharmaceutical companies and research institutions in the U.S., Canada and around the world.
PhenoPath’s test menu includes a broad array of state-of-the-art immunohistochemistry, flow cytometry, fluorescence in situ hybridization and molecular assays as well as chromosome analysis.
PhenoPath now offers EGFR mutation testing using cell-free DNA isolated from plasma. Please see the links below for more information:
Please see Biomarker Testing for Checkpoint Inhibitors for more information on PD-L1 22C3, PD-L1 28-8 and PD-L1 SP142.
New FDA Approvals for PD-L1/PD-1 Targeted Therapies & Introducing the Combined Positive Score (CPS); New Assays MUC4 IHC and TFE3 (Xp11) FISH; Amyloid Analysis;...Read More »
PhenoPath newsletter featuring the latest on RAS gene testing, "double-hit" B cell lymphomas, and a new marker for small cell carcinoma of the ovary.... Read More »
PhenoPath is pleased to announce the launch of extended RAS gene testing. Beginning June 5, 2017, PhenoPath will offer in-house KRAS and NRAS testing that...Read More »